Pennsylvania is currently home to 3307 active clinical trials, seeking participants for engagement in research studies. These trials take place at a variety of cities in the state, including Philadelphia, Pittsburgh, Hershey and Allentown. Whether you're a healthy volunteer interested in paid medical research or someone seeking trials related to a specific condition, the state offers a diverse array of opportunities in your vicinity.
Deep Brain Stimulation Effects in Patients with Opioid Use Disorder
NCT04354077
Recruiting
This is a pilot study to evaluate the safety and efficacy of deep brain stimulation (DBS) of the nucleus accumbens (NAc) as adjunctive treatment for treatment-refractory opioid use disorder. This study will include 3 individuals with opioid use disorder and relapsing opioid use despite active participation in a drug addiction treatment program.
Gender:
ALL
Ages:
Between 22 years and 65 years
Trial Updated:
01/23/2025
Locations: AHN Allegheny General Hospital, Pittsburgh, Pennsylvania
Conditions: Opioid-use Disorder
Register for Updates
iLookOut for Child Abuse: Micro-learning to Improve Knowledge Retention
NCT04324619
Recruiting
This proposed randomized controlled trial will examine whether gamified micro-learning is a feasible and effective way to promote long-term learning about child abuse and its reporting. After completing the interactive online learning program, iLookOut for Child Abuse, early childhood professionals will receive brief (5-10 minute) gamified learning exercises to complete on their smart-phones. By measuring knowledge (and other outcomes) over time, the investigators will determine how much knowled... Read More
Gender:
ALL
Ages:
Between 18 years and 100 years
Trial Updated:
01/23/2025
Locations: Penn State Milton S. Hershey Medical Center / Penn State College of Medicine, Hershey, Pennsylvania
Conditions: Child Abuse
Register for Updates
iLookOut for Child Abuse -Online Learning Module for Early Childcare Providers
NCT02225301
Recruiting
Phase 1 was a randomized control trial that used a test-retest model to evaluate the impact of iLook Out for Child Abuse, an online, interactive learning module about reporting suspected child abuse. Delivered via a learning management system to early childhood professionals who work with infants and young children, this study assessed iLookOut's effect on 1) knowledge about reporting suspected child abuse; 2) attitudes toward reporting suspected child abuse; and 3) preparedness to protect child... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
01/23/2025
Locations: Penn State Milton S. Hershey Medical Center / Penn State College of Medicine, Hershey, Pennsylvania
Conditions: Child Abuse, Child Neglect, Child Maltreatment
Register for Updates
Evaluating the Durability of Closure for Venous Leg Ulcers
NCT06697925
Recruiting
The goal of this observational study is to determine the durability of closure for venous leg ulcer subjects that achieved closure in the THOR trial.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
01/22/2025
Locations: Serena Group, Monroeville, Pennsylvania
Conditions: Venous Leg, Venous Leg Ulcer (VLU), Venous Leg Ulcer, Venous Ulcer, VLU
Register for Updates
Evaluating Intact Fish Skin Graft and Standard of Care Versus Standard of Care Alone in Nonhealing Venous Leg Ulcers
NCT06693570
Recruiting
The purpose of this study is to determine the between-arm difference in the proportion of subjects achieving complete closure of hard-to-heal venous leg ulcers (VLU) between Intact Fish Skin Graft plus standard of care (IFSG/SOC) versus standard of care alone (SOC) over 12 weeks.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
01/22/2025
Locations: Serena Group- Monroeville, Monroeville, Pennsylvania
Conditions: Venous Leg Ulcer (VLU), Venous Leg Ulcers, Venous Leg, Nonhealing Venous Leg Ulcer
Register for Updates
BINGO: Bridging Knowledge, Increasing Awareness
NCT06504407
Recruiting
The U.S. population is becoming more diverse, but minority groups are still significantly underrepresented in cancer clinical trials. This disparity limits our understanding of how treatments work across different populations. Efforts like the 21st Century Cures Act aim to improve inclusion, but challenges persist due to historical mistrust and complex barriers in healthcare. To address these issues, Penn State Health is using a fun and educational approach called "BINGO" to engage the African... Read More
Gender:
FEMALE
Ages:
18 years and above
Trial Updated:
01/22/2025
Locations: Penn State Cancer Institute, Hershey, Pennsylvania
Conditions: Cancer Education, Health Equity
Register for Updates
Neutrophil and Monocyte Deactivation Via the SeLective CytopheretIc Device - a Randomized Clinical Trial in Acute Kidney Injury
NCT05758077
Recruiting
This randomized, controlled, pivotal study is intended to determine whether up to ten sequential 24-hour treatments with the Selective Cytopheretic Device (SCD) will improve survival in patients with Acute Kidney Injury (AKI) requiring continuous kidney replacement therapy (CKRT) when compared to CKRT alone (standard of care). This study is further intended to determine whether SCD therapy will reduce the duration of maintenance dialysis secondary to AKI. This study will enroll approximately 200... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
01/22/2025
Locations: St Luke's University Hospital, Bethlehem, Pennsylvania
Conditions: Acute Kidney Injury
Register for Updates
A Study of CYP-001 in Combination with Corticosteroids in Adults with High-risk AGvHD
NCT05643638
Recruiting
This study is a prospective randomized placebo-controlled phase 2 study to compare CYP-001 plus corticosteroids (CS) to placebo plus CS in allogeneic hematologic stem cell transplant recipients with HR-aGvHD. Severity of GvHD will be assessed at screening and throughout the study using Mount Sinai Acute GvHD International Consortium (MAGIC) guidelines. Eligible subjects will be randomized to receive either CYP-001 IV infusion on Days 0 and 4 or placebo on the same days. All subjects will receive... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
01/22/2025
Locations: Penn State Health, Hershey, Pennsylvania
Conditions: Graft Versus Host Disease, Acute
Register for Updates
A Study of TSC-100 and TSC-101 in AML, ALL and MDS Patients Undergoing Haploidentical Donor Transplantation
NCT05473910
Recruiting
This is a multi-center, non-randomized, concurrent controlled, multi-arm, Phase 1 interventional, open-label, biologic assignment-based umbrella study evaluating the feasibility, safety and preliminary efficacy of an escalating dose regimen of up to 2 doses of TSC-100 and TSC-101 in patients with AML, MDS, or ALL following HCT from a haploidentical donor.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
01/22/2025
Locations: UPenn, Philadelphia, Pennsylvania
Conditions: AML, Myelodysplastic Syndromes, ALL, Adult
Register for Updates
Electronic Cigarette-derived Oxidants and Cardiopulmonary Effects
NCT05239793
Recruiting
This is a pilot study on the impact of switching from cigarettes to Electronic Cigarettes (EC) on disease-related clinical symptoms and biomarkers of harm in smokers with preexisting Chronic Obstructive Pulmonary Disease (COPD). The researchers hypothesize that the smokers who switch to EC completely or significantly will experience reduced COPD symptoms, risks of exacerbations, and decreased levels of oxidative stress and inflammation.
Gender:
ALL
Ages:
Between 21 years and 74 years
Trial Updated:
01/22/2025
Locations: Penn State Health Milton S. Hershey Medical Center, Hershey, Pennsylvania
Conditions: Chronic Obstructive Pulmonary Disease
Register for Updates
Clinical Study of Cannabidiol in Children, Adolescents, and Young Adults with Fragile X Syndrome
NCT04977986
Recruiting
This is a randomized, double-blind, placebo-controlled, multiple-center study, to assess the efficacy and safety of Cannabidiol administered as ZYN002 for the treatment of children, adolescent, and young adult patients with Fragile X Syndrome (FXS). Eligible participants will participate in up to an 18-week treatment period, where all participants will receive placebo or active study drug. Patients ages 3 to \< 30 years will be eligible to participate.
Gender:
ALL
Ages:
Between 3 years and 29 years
Trial Updated:
01/22/2025
Locations: Penn State Hershey Medical Center, Hershey, Pennsylvania
Conditions: Fragile X Syndrome
Register for Updates
Validation of Oxygen Nanosensor in Mitochondrial Myopathy
NCT04086329
Recruiting
Past mitochondrial disease treatment studies have been unsuccessful in determining treatment efficacy, and a major factor has been the lack of validated biomarkers in mitochondrial myopathy (MM). There is currently a growing number of potential new treatments to be tested through MM clinical intervention trials, which has created a pressing need for quantitative biomarkers that reliably reflect MM disease severity, progression, and therapeutic response. The purpose of the study is to measure th... Read More
Gender:
ALL
Ages:
Between 18 years and 65 years
Trial Updated:
01/22/2025
Locations: The Children's Hospital of Philadelphia, Philadelphia, Pennsylvania
Conditions: Mitochondrial Myopathies, Mitochondrial Diseases
Register for Updates